|
|
Article: Novacea, Aventis Move Calcitriol Into Prostate Cancer Phase II/III.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Novacea Inc. began a Phase II/III trial of DN-101, its own formulation of calcitriol, which will be studied in combination with Taxotere as a potential treatment for androgen-independent prostate cancer.
Novacea, of South San Francisco, was founded in July 2001 by Domain Associates and has raised $12 million to date, said M.J. Whitehouse, vice president of early development at Novacea.
"It's our first Phase II trial, so I think it represents very rapid progress in the clinic for a company to be in a large Phase II study within 14 months of its initiation," Whitehouse told BioWorld Today.
Eckard Weber, a venture partner at ...